KFDA approves Diovan for Heart Failure
Published: 2003-04-16 06:56:00
Updated: 2003-04-16 06:56:00
Novartis Korea said that the Korea Food and Drug Administration approved an antihypertensive agent Diovan (valsartan) to treat heart failure in patients who are intolerant of angiotensin-converting-enzyme (ACE) inhibitors, a common type of heart failure therapy.
Diovan, an angiotensin II recep...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
